Vol 62, Supp. II (2011)
Review paper
Submitted: 2013-02-15
Published online: 2011-09-21
Denosumab — a new option in the treatment of osteoporosis
Edward Franek
Vol 62, Supp. II (2011)
Review Article
Submitted: 2013-02-15
Published online: 2011-09-21
Abstract
Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is
associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading
to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases.
Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function
impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular
risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the
majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can
definitely be confirmed.
(Pol J Endocrinol 2011; 62 (education supplement II): 37–41)
Abstract
Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is
associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading
to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases.
Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function
impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular
risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the
majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can
definitely be confirmed.
(Pol J Endocrinol 2011; 62 (education supplement II): 37–41)
Keywords
denosumab; RANK; RANKL; fractures
Title
Denosumab — a new option in the treatment of osteoporosis
Journal
Endokrynologia Polska
Issue
Vol 62, Supp. II (2011)
Article type
Review paper
Pages
37-41
Published online
2011-09-21
Page views
598
Article views/downloads
788
Keywords
denosumab
RANK
RANKL
fractures